Evidence map›Paper›PMID 41609975›Full record

ReviewOphthalmology and therapy2026

LipiFlow and the Transformation of Therapeutic Meibomian Gland Expression into Routine Clinical Practice.

Caroline A Blackie, David Murakami, Eric Donnenfeld, Heather S Oliff

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Caroline A BlackieJohnson & Johnson Surgical Vision, Inc., Irvine, CA, 92618, USA. cblackie@its.jnj.com.ORCID http://orcid.org/0000-0002-4618-3303
David MurakamiJohnson & Johnson Surgical Vision, Inc., Irvine, CA, 92618, USA.ORCID http://orcid.org/0009-0006-1939-1947
Eric DonnenfeldNYU Department of Ophthalmology, Garden City, NY, USA.ORCID http://orcid.org/0000-0002-5235-1780
Heather S OliffScience Consulting Group, LLC, Tustin, CA, USA.ORCID http://orcid.org/0009-0005-5959-0046

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2011, meibomian gland dysfunction (MGD) was officially recognized as a condition that necessitated treatment with the goal of improving ocular symptoms. This was a tipping point in the understanding of MGD and the need for treatment. After 2011, there was an exponential increase in the research of MGD and treatment modalities. This commentary aims to provide information for clinicians to understand the value of in-office treatments with LipiFlow and the inherent differences in efficacy, patient/doctor experience, compliance, and safety of other treatment modalities. Also, the aim of this commentary is to describe how LipiFlow Thermal Pulsation System contributed to the evolution of MGD management by transforming therapeutic gland expression from an underutilized intervention into a widely adopted, evidence-based standard of care.

Indexed as

Dry eyeHistoryLipiFlowMeibomian gland dysfunctionOcular surface diseaseVectored thermal pulsation systemWarm compress

Identifiers

PMID41609975
PMCPMC12900989

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.